ChroMedX Announces Operations Update and Advisory Board Appointment
October 28, 2014
ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide a HemoPalm development update and announce Dr. Cynthia Balion as the first appointment to the Company's Technical Advisory Board.
Dr. Wayne Maddever, P.Eng., Chief Executive Officer of ChroMedX Corp. is pleased to provide the following update on the Company's HemoPalm development programme and addition to ChroMedX's Technical Advisory Board.
"Led by ALine Inc., HemoPalm development has progressed as planned and continues to be on target for completion of the prototype in Q1, 2015. Key components have been received including calibration fluid pouches manufactured in Germany, which are essential for biosensor calibration and stability testing of the contents of the calibration pouches has commenced in Ontario, Canada. Other key components including microspectrometers, have been ordered and delivery is expected within the next 2-3 weeks. Testing of the microspectrometers will be performed jointly between ALine in Rancho Domingo, CA., and Ontario, Canada"
"We are very pleased to welcome Dr. Cynthia Balion, Associate Professor of Pathology and Molecular Medicine, McMaster University as the initial member of the Company's Technical Advisory Board."
Dr. Balion is also a clinical biochemist for the Hamilton Regional Laboratory Medicine Program (HRLMP) and co-investigator for the Canadian Longitudinal Study on Aging (CLSA) where she is the director of the Biorepository and Bioanalysis Centre.
The CLSA is a large, national, long-term study that follows 50,000 men and women between the ages of 45 and 85 for 20 years. As the most comprehensive study of health and aging in Canada, the CLSA collects information on the changing biological, medical, psychological, social, lifestyle and economic aspects of people's lives as they age.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
President, CEO & Director
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com